- 专利标题： Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
-
申请号： US16038729申请日： 2018-07-18
-
公开(公告)号： US10471160B2公开(公告)日： 2019-11-12
- 发明人: Matthias Eder , Klaus Kopka , Martin Schäfer , Ulrike Bauder-Wüst , Uwe Haberkorn , Michael Eisenhut , Walter Mier , Martina Benesova , Hans-Christian Kliem , Clemens Kratochwil
- 申请人： DEUTSCHES KREBSFORSCHUNGSZENTRUM , RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
- 申请人地址： DE Heidelberg DE Heidelberg
- 专利权人： DEUTSCHES KREBSFORSCHUNGSZENTRUM,RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
- 当前专利权人： DEUTSCHES KREBSFORSCHUNGSZENTRUM,RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
- 当前专利权人地址： DE Heidelberg DE Heidelberg
- 代理机构： The Marbury Law Group, PLLC
- 优先权： EP13004991 20131018; EP14175612 20140703
- 主分类号： A61K51/04
- IPC分类号： A61K51/04 ; C07D257/02 ; C07B59/00 ; C07D295/145
摘要：
The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
公开/授权文献
信息查询
